Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy ...

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more ...

Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, ...

Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel.

If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...

Communication must be viewed as more than the last step of the research process. It is the structure that makes scientific ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...